Purpose
Below are recent publications related to vaccines in CDC's Morbidity and Mortality Weekly Report (MMWR).
2026
- Hill H, Yankey D, Elam-Evans L, Mu Y, Chen M, Stokley S, et al. Vaccination Coverage by Age 24 Months Among Children Born in 2021 and 2022 — National Immunization Survey-Child, United States, 2022–2024 MMWR 2026./ 75(11);146–155
This report describes trends in national coverage with recommended vaccines over time (excluding COVID-19 vaccine) and provides coverage estimates by Vaccines for Children program eligibility, race and ethnicity, poverty status, urbanicity, and jurisdiction of residence.
- Maloney P, Reeves E, Wielgosz K, Price A, Natarajan K, DeSilva M, et al. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — United States, September 2025–February 2026 MMWR 2026./ 75(9);116–123
This report provides interim estimates of 2025–26 influenza vaccine effectiveness against outpatient visits and hospitalization for laboratory-confirmed influenza among children, adolescents, and adults from three U.S. surveillance networks.
- Zhu S, Quint J, León T, Li N, Muldrew S, Porse C, et al. Interim Estimates of 2025–26 Seasonal Influenza Vaccine Effectiveness — California, October 2025–January 2026 MMWR 2026./ 75(9);124–128
This report provides interim estimates of 2025–26 seasonal influenza vaccine effectiveness against a positive laboratory test result for influenza A or B in California during October 2025–January 2026.
- Stanislawski E, Romero A, Holzinger N, Healy R, Webb N, Cruz K, et al. Measles Outbreak — New Mexico, 2025 MMWR 2026./ 75(9);111–115
This report highlights how coordinating public communication and improving access to MMR vaccine can support vaccine administration across large, rural areas and contribute to a measles outbreak response.
- Alak M, Latorre M, Foster P, Armstrong J, Levent F, Chen M, et al. Notes from the Field: Congenital Rubella Syndrome — Florida, 2025 MMWR 2026. / 75(8);106–107
This report details the case of an infant with Congenital Rubella Syndrome who was born to a mother from a country that had not introduced rubella vaccine.
- Raykin J, Rochin I, Wiegand R, Soto V, Nyame-Mireku A, Chung A, et al. COVID-19 Antiviral Prescription Receipt Among Outpatients Aged ≥65 Years — United States, June 1, 2023–September 30, 2025 MMWR 2026./75(6);69–76
This report evaluated the frequency of antiviral prescriptions and the factors associated with their receipt among adults aged ≥65 years with COVID-19 who were examined in outpatient settings during June 2023–September 2025.
- Silk B, Prill M, Winn A, Patton M, Moline H, Melgar M, et al. Respiratory Virus Activity — United States, July 1, 2024–June 30, 2025 MMWR 2026./ 75(6);77–84
This report summarizes U.S. trends in endemic respiratory virus activity during July 2024–June 2025.
- Metz A, Barnes M, Andresen K, Stringer G, Comstock N, Burakoff A, et al. Measles Outbreak Associated with an Infectious Traveler — Colorado, May–June 2025 MMWR 2026. / 75(4);48–54
This report describes measles cases in Colorado residents that were part of an outbreak resulting from exposure to a patient who was infectious during air travel.
- Jensen G, Gidfar C, Weisbeck K, Barnes M, Minnerath E, Matzinger S, et al. Notes from the Field: Wastewater Surveillance for Measles Virus During a Measles Outbreak — Colorado, August 2025 MMWR 2026. / 75(2);20–2
This report describes the detection of measles virus through wastewater surveillance in Mesa County and its contribution to the subsequent outbreak response.
- Barger A, Margrey SF, Siu AW, Wallace R, Earnest R, Frankel M, et al. Imported Human Rabies — Kentucky and Ohio, 2024 MMWR 2026. / 75(2);23–7
This report describes the patient’s signs and symptoms, hospital course, and the subsequent contact tracing activities once a diagnosis of rabies was confirmed.
- Amin AB, Collins JP, Doug X, Leidner AJ, Loehr J, Moser CA, McNamara LA. Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025 MMWR 2026. / 75(1);7–14
This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-CRM/MenB-4C.